本帖最后由 老马 于 2012-1-13 21:20 编辑 ; q' k6 o- d+ ]* l0 @6 N
6 A/ n: y1 g( n4 u' ^! Y- E
爱必妥和阿瓦斯丁的比较
$ m! Y; C6 \7 w5 W, m( Y. D
i# O& T+ p# g" r6 g
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/- O" W1 H+ T/ N8 W
% g: e) F5 }0 | j
( z" U! p% Q' x* F
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/; m& e$ I3 a$ O* l. ?6 p! N6 y. q# k
==================================================
4 X# c( \* B$ b4 Q N* P3 B- zOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)1 B) p% W3 ^) h! K7 L8 r
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.# o0 [/ e5 S$ j) |- R3 p! F
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
- c9 b& [6 B M
|